These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 12463275)

  • 21. Meeting acute migraine treatment needs through novel treatment formulations.
    Silberstein SD
    Neurotherapeutics; 2010 Apr; 7(2):153-8. PubMed ID: 20430313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symptomatic treatment of migraine in children: a systematic review of medication trials.
    Damen L; Bruijn JK; Verhagen AP; Berger MY; Passchier J; Koes BW
    Pediatrics; 2005 Aug; 116(2):e295-302. PubMed ID: 16061583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 5-HT
    Whealy M; Becker WJ
    Handb Clin Neurol; 2024; 199():17-42. PubMed ID: 38307644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of dihydroergotamine (DHE) should be restricted to no more than twice a week.
    Tfelt-Hansen PC; Diener HC
    Headache; 2014 Oct; 54(9):1523-5. PubMed ID: 24862945
    [No Abstract]   [Full Text] [Related]  

  • 26. [The problems of migraine headache treatment].
    Vilionskis A; Vaitkus A
    Medicina (Kaunas); 2002; 38(7):679-84. PubMed ID: 12474651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
    Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
    J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coronary side-effect potential of current and prospective antimigraine drugs.
    MaassenVanDenBrink A; Reekers M; Bax WA; Ferrari MD; Saxena PR
    Circulation; 1998 Jul; 98(1):25-30. PubMed ID: 9665056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of ergotamine and sumatriptan use in the Netherlands from 1991 to 1997.
    Rahimtoola H; Egberts AC; Buurma H; Tijssen CC; Leufkens HG
    Cephalalgia; 2001 Jun; 21(5):596-603. PubMed ID: 11472386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience.
    Wilkinson M; Pfaffenrath V; Schoenen J; Diener HC; Steiner TJ
    Cephalalgia; 1995 Oct; 15(5):337-57. PubMed ID: 8536293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives.
    Young WB
    Headache; 1997; 37 Suppl 1():S42-5. PubMed ID: 9009473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.
    Plosker GL; McTavish D
    Drugs; 1994 Apr; 47(4):622-51. PubMed ID: 7516861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute treatment of paediatric migraine: a meta-analysis of efficacy.
    Silver S; Gano D; Gerretsen P
    J Paediatr Child Health; 2008 Jan; 44(1-2):3-9. PubMed ID: 17854415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
    Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat.
    Tfelt-Hansen P
    Cephalalgia; 1998 Oct; 18(8):532-8. PubMed ID: 9827244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal papillary necrosis following emergency department treatment of migraine.
    Witting MD
    J Emerg Med; 1996; 14(3):373-6. PubMed ID: 8782036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triptans: actions and reactions.
    Nahas SJ; Silberstein SD
    Headache; 2008 Apr; 48(4):611-3. PubMed ID: 18377383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Commentary.
    Rothrock JF
    Headache; 2011 Apr; 51(4):518-9. PubMed ID: 21457236
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.